Detailed price information for Global Listed Private Equity ETF (PEX-A) from The Globe and Mail including charting and trades.

The APOLLO trial showed that anlotinib plus penpulimab offers a promising benefit–risk profile as a first-line treatment for patients with unresectable HCC. Anlotinib plus penpulimab could be a new ...